Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens
- 25 June 2020
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 76 (11) , 1557-1565
Abstract
Purpose Para-aminosalicylic acid (PAS) is currently one of the add-on group C medicines recommended by the World Health Organization for multidrug-resistant tuberculosis treatment. At the recommended doses (8–12 g per day in two to three divided doses) of the widely available slow-release PAS formulation, studies suggest PAS exposures are lower than those reached with older PAS salt formulations and do not generate bactericidal activity. Understanding the PASER dose-exposure–response relationship is crucial for dose optimization. The objective of our study was to establish a representative population pharmacokinetics model for PASER and evaluate the probability of bactericidal and bacteriostatic target attainment with different dosing regimens. Methods To this end, we validated and optimized a previously published population pharmacokinetic model on an extended dataset. The probability of target attainment was evaluated for once-daily doses of 12 g, 14 g, 16 g and 20 g PASER. Results The final optimized model included the addition of variability in bioavailability and allometric scaling with body weight on disposition parameters. Peak PAS concentrations over minimum inhibitory concentration of 100, which is required for bactericidal activity are achieved in 53%, 65%, 72% and 84% of patients administered 12, 14, 16 and 20 g once-daily PASER, respectively, when MIC is 1 mg/L. For the typical individual, the exposure remained above 1 mg/L for ≥ 98% of the dosing interval in all the evaluated PASER regimens. Conclusion The pharmacokinetic/pharmacodynamic parameters linked to bactericidal activity should be determined for 14 g, 16 g and 20 g once-daily doses of PASER.Keywords
This publication has 25 references indexed in Scilit:
- Para-Aminosalicylic Acid Plasma Concentrations in Children in Comparison with Adults after Receiving a Granular Slow-Release PreparationJournal of Tropical Pediatrics, 2012
- Bioavailability of Aminosalicylic Acid and Its Various Salts in Humans III: Absorption from TabletsJournal of Pharmaceutical Sciences, 1974
- Para-aminosalicylic-acid (PAS) concentrations in the serum during treatment with various PAS preparationsTubercle, 1959
- The treatment of pulmonary tuberculosis with intravenous PAS-infusionsTubercle, 1955
- Various Combinations of Isoniazid with Streptomycin or with P.A.S. in the Treatment of Pulmonary Tuberculosis: Seventh Report to the Medical Research CouncilBMJ, 1955
- Intravenous P.A.S. in relation to pulmonary tuberculotherapy: With an account of 1,145 transfusionsBritish Journal of Tuberculosis and Diseases of the Chest, 1954
- Isoniazid in Combination with Streptomycin or with P.A.S. in the Treatment of Pulmonary TuberculosisBMJ, 1953
- Prevention of Streptomycin Resistance by Combined Chemotherapy: Medical Research Council InvestigationBMJ, 1952
- Die tuberkulostatische Wirksamkeit verschiedener PAS-Präparate in vitroDMW - Deutsche Medizinische Wochenschrift, 1950
- Weitere Erfahrungen mit Streptomycin, PAS und TBI (Conteben) in der Behandlung der internen TuberkulosenDMW - Deutsche Medizinische Wochenschrift, 1950